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Abstract
Colorectal cancer (CRC) has high mortality rates, especially in patients with advanced disease stages, who often do not 
respond to therapy. The cellular components of the tumor microenvironment are essentially responsible for dictating disease 
progression and response to therapy. Expansion of different myeloid cell subsets in CRC tumors has been reported previ-
ously. However, tumor-infiltrating myeloid cells have both pro- and anti-tumor roles in disease progression. In this study, we 
performed transcriptomic profiling of cells of myeloid lineage  (CD33+) from bulk CRC tumors at varying disease stages. We 
identified differentially expressed genes and pathways between CRC patients with advanced stage and early stages. We found 
that pro-angiogenic and hypoxia-related genes were upregulated, while genes related to immune and inflammatory responses 
were downregulated in  CD33+ myeloid cells from patients with advanced stages, implying that immune cell recruitment and 
activation could be compromised in advanced disease stages. Moreover, we identified a unique “poor prognosis  CD33+ gene 
signature” by aligning top upregulated and downregulated genes in tumor-infiltrating myeloid cells from our analyses with 
data from The Cancer Genome Atlas. Our results showed that this gene signature is an independent prognostic indicator for 
disease-specific survival in CRC patients, potentially reflecting its clinical importance.
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Abbreviations
CRC  Colorectal cancer
DAVID  Database for annotation, visualization and 
integrated discovery
DSS  Disease-specific survival
DEGs  Differentially expressed genes
ICI  Immune checkpoint inhibitor
MDSC  Myeloid-derived suppressor cell
PCA  Principle component analysis
PFI  Progression-free interval
ppCD33sig  Poor prognosis CD33 gene signature
PPI  Protein–protein interaction
TAM  Tumor-associated macrophage
TAN  Tumor-associated neutrophil
TCGA  The cancer genome atlas
Treg  T regulatory cell
Introduction
Colorectal cancer (CRC) is the third leading cause of all 
cancer-related deaths in the world, and its incidence is 
about threefold higher in developed countries compared 
to rest of the world [1]. CRC comprises a heterogeneous 
group of diseases, resulting from the combined effects 
of various mutations and mutagens [2]. Patients with 
advanced-stage/metastatic CRC mainly receive palliative 
therapies for disease management, and majority of thera-
pies prove ineffective. Drug resistance and tumor recur-
rence are common in these patients, leading to the dev-
astating mortality rates of CRC [3]. Emerging evidences 
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have shown that investigating the transcriptome of CRC 
tumors can provide better insights into tumor characteris-
tics and assist to predict response to treatment [4]. Addi-
tionally, the immune cellular components of the tumor 
microenvironment (TME) are largely responsible for 
response to therapies [5]. Therefore, it is vital to explore 
their molecular characteristics, which contribute to various 
mechanisms/pathways to aid tumor progression.
Myeloid cells can be present as the most abundant cell 
type in the TME and affect patient outcomes in many cancer 
types [6]. Cells of myeloid lineage reach terminal differen-
tiation and are trafficked to the TME in response to specific 
colony-stimulating factors and soluble cytokines. Myeloid 
cells in the TME carry out both pro- and anti-tumor roles. 
For instance, monocytes/macrophages/monocyte-derived 
dendritic cells (Mo-DCs) in the TME may be involved in 
phagocytosis, secretion of tumoricidal mediators, promotion 
of angiogenesis, remodeling of the extracellular matrix and 
recruitment of lymphocytes [7]. While, tumor-infiltrating 
myeloid antigen-presenting cells are involved in T cell acti-
vation, immunosuppressive myeloid cells, such as tumor-
associated macrophages (TAMs) and myeloid-derived sup-
pressive cells (MDSCs), hamper anti-tumor therapies and 
assist disease progression [8]. MDSCs are immunosuppres-
sive cells that have been associated with worse prognosis in 
various solid tumors and malignancies [9, 10]. MDSCs are 
recruited to the TME in response to various factors produced 
by the tumor stroma (e.g., pro-inflammatory cytokines, 
HMGB1), prostaglandin E2 (PGE2) and cyclooxygenase 2 
(COX2) [9]. Numerous studies have reported the expansion 
of myeloid suppressor cells in the TME of CRC patients 
and their associations with disease progression [11–13]. 
However, uncovering pathways and mechanisms employed 
by myeloid cells in the TME, in addition to their role in 
response to virtually all therapeutic modalities, are largely 
unknown.
In this study, we sorted tumor-infiltrating myeloid cells 
from bulk tumors of CRC patients with varying disease 
stages, and performed comprehensive transcriptomic anal-
yses to reveal their possible roles in disease progression. 
Our data highlighted the various unique and overlapping 
pathways shared between tumor-infiltrating myeloid cells 
of patients with varying disease stages. Aligning our data 
with The Cancer Genome Atlas (TCGA) for colon and rectal 
cancer enabled us to identify a distinct gene signature of 
tumor-infiltrating myeloid cells in CRC patients that serves 
as an independent prognostic indicator for disease-specific 
survival, referred to as “the poor prognosis  CD33+ gene 
signature”. Collectively, our findings can have important 
implications on the current knowledge of myeloid cell con-
tributions to disease progression in CRC patients.
Materials and methods
Sample collection and storage
Tumor tissues (TT) were obtained from treatment-naïve 
CRC patients (n = 13), who underwent surgery at Hamad 
Medical Corporation, Doha, Qatar. Table 1 shows the clini-
cal and pathological features of all participating patients. All 
patients included in this study provided written informed 
consent prior to sample collection. This study was executed 
under ethical approvals from Hamad Medical Corpora-
tion, Doha, Qatar (protocol no. MRC-02-18-012) and Qatar 
Biomedical Research Institute, Doha, Qatar (protocol no. 
2017-006). All experiments were executed in accordance 
with applicable guidelines and regulations.
Tissue specimens were cut into small pieces and frozen 
in 1 ml of freezing medium [40% RPMI-1640 medium (Life 
Technologies, New York, USA), 50% fetal calf serum (FCS; 
Hyclone, GE Healthcare Life Sciences, Utah, USA) and 10% 
dimethylsulfoxide (DMSO; Sigma-Aldrich, Missouri, USA) 
and stored in liquid nitrogen to be used in batches for subse-
quent analyses, as previously described [14].
Dissociation of tissues
Cell suspensions were prepared from bulk TT by mechani-
cal dissociation, as previously described [14]. Briefly, fro-
zen TT were thawed and washed with phosphate-buffered 
saline (PBS) and cut into small pieces (~ 2–4 mm) using a 
surgical scalpel. Cell dissociation was performed using gen-
tleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, 
Germany) without enzymatic digestion. Cell suspension was 
then passed through a 100-µM cell strainer to remove cell 
aggregates and debris, and washed multiple times with PBS.
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Cell sorting
Single-cell suspensions from TT were resuspended in 
100-µl flow cytometry staining buffer (PBS with 1% FCS 
and 0.1% sodium azide). Fc receptors (FcR) were blocked 
using FcR Blocking Reagent (Miltenyi Biotech, Bergisch 
Gladbach, Germany), and 7-AAD viability dye (eBiosci-
ence, San Diego, USA) was used to gate live cells. Cells 
were stained with cell surface antibodies against CD3-
allophycocyanin-Cy7 (clone SK7, BD Pharmingen, San 
Jose, USA) and CD33-allophycocyanin (clone WM53, BD 
Pharmingen). Cells were washed twice with flow cytom-
etry staining buffer and re-suspended in Pre-Sort buffer 
(BD Biosciences). BD FACSAria III SORP cell sorter on 
BD FACSDiva software (BD Biosciences) was used for 
sorting pure  CD33+(7AAD–CD3–CD33+) populations. 
Relevant procedures were followed to ensure minimum 
sorter-induced cell stress (SICS), as previously described 
[15]. Flow cytometric representations were performed on 
FlowJo V10 software (FlowJo, Ashland, USA).
RNA extraction and amplification
Total RNA was isolated from sorted, pure tumor-infil-
trating  CD33+ myeloid cells, from 13 CRC patients using 
RNA/DNA/protein purification Plus Micro Kit (Norgen 
Biotek Corporation, Ontario, Canada) according to the 
manufacture’s protocol. RNA was then amplified using 5X 
MessageAmp™ II aRNA Amplification Kit (Invitrogen) as 
per the manufacture’s protocol. RNA concentrations were 
determined using Qubit RNA HS or Broad Range Assay 
Kits (Invitrogen, California, USA).
Quantitative real‑time reverse transcriptase PCR 
(qRT‑PCR)
Purified RNA (1 µg) was reversely transcribed to cDNA 
using QuantiTect Reverse Transcription Kit (Qiagen). PCR 
reactions for ARG1, IDO1, IL1B, CCR2, CD274, LGALS9 
and β-actin were performed using PowerUp SYBR Green 
Master Mix (Applied Biosystems) and QuantStudio 6/7 
Flex Real-time PCR system (Applied Biosystems, Cali-
fornia, USA). Relative gene expression was normalized to 
β-actin and calculated using  2−ΔΔCT method. Additionally, 
the relative expression for each gene was calculated by 
normalizing the expression in  CD33+ cells to data from 
sorted tumor-infiltrating  CD8+ T cells from the same 
patients [16], after the initial normalization to β-actin. 
Primer sequences are presented in Table 2.
Library preparation
cDNA libraries were generated amplified RNA using Exome 
TruSeq Stranded mRNA Library Prep Kit (illumina, San 
Diego, USA) according to the manufacturer’s protocol, and 
as previously described [17]. Quality passed libraries were 
subjected to clustering using TruSeq PE Cluster Kit v3-cBot-
HS (illumina). The clustered samples were sequenced on an 
illumina HiSeq 4000 instrument using HiSeq 3000/4000 
SBS kit (illumina).
RNA‑Sequencing data processing and analyses
RNA-Seq data were analyzed and illustrated using multiple 
bioinformatics tools. Pair end reads were quality-trimmed 
and aligned to the hg19 human reference genome in CLC 
Genomics Workbench 12 (Qiagen) [17]. The levels of 
expression of transcripts were measured as the score of 
TPM (Transcripts Per Million) mapped reads. Abundance 
data were subsequently subjected to differential gene expres-
sion analyses to compare transcriptome of tumor-infiltrating 
 CD33high myeloid cells from CRC patients with advanced 
stages versus early stages. The Z-scores were calculated 
from the TPM values as previously described [18]. Differen-
tial expression analyses were also performed to compare the 
transcriptomes of sorted tumor-infiltrating  CD33high myeloid 
cells with transcriptome of sorted tumor-infiltrating  CD8+ 
T cells (used as controls) from the same patient cohort [16].
Volcano plots were generated using OriginPro 2020 soft-
ware (OriginLab Corporation, Massachusetts, USA) with 
Log2 FC > 2 and P value cutoff < 0.05. The Gene Ontol-
ogy (GO) analysis and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway enrichment analyses of dif-
ferentially expressed genes (DEGs) were performed by the 
Table 2  Primer sequences for qRT-PCR
Primer Sequence
ARG1 Forward, 5′- GTG GAA ACT TGC ATG GAC AAC -3′
Reverse, 5′- AAT CCT GGC ACA TCG GGA ATC -3′
IDO Forward, 5′- GCC AGC TTC GAG AAA GAG TTG -3′
Reverse, 5′- ATC CCA GAA CTA GAC GTG CAA -3′
IL1B Forward, 5′- ATG ATG GCT TAT TAC AGT GGCAA -3′
Reverse, 5′- GTC GGA GAT TCG TAG CTG GA -3′
IL6 Forward, 5′- ACT CAC CTC TTC AGA ACG AATTG -3’
Reverse, 5′- CCA TCT TTG GAA GGT TCA GGTTG -3′
CCR2 Forward, 5′- CCA CAT CTC GTT CTC GGT TTATC -3′
Reverse, 5′- CAG GGA GCA CCG TAA TCA TAATC-3′
CD274 Forward, 5′- TGG CAT TTG CTG AAC GCA TTT -3′
Reverse, 5′- TGC AGC CAG GTC TAA TTG TTTT -3′
LGALS9 Forward, 5′- GGG CGC AGA CAA AAA CCT C -3′
Reverse, 5′- GGA GTA GAG AAC ATC TGT CCAGG -3′
β-actin Forward, 5′- AGA GCT ACG AGC TGC CTG AC -3′
Reverse, 5′- AGC ACT GTG TTG GCG TAC AG -3′
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Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) tool, as previously described [19]. PCA 
plots and gene ontology clustering were performed using 
Integrated Differential Expression and Pathway (iDEP.91, 
South Dakota State University, USA) online analysis tool. 
Raw TPM values were uploaded and computed to iden-
tify and generate various illustrations for DEGs. K-Means 
clustering (iDEP.91) and STRING (https ://strin g-db.org/, 
ELIXIR Core Data Resources) were used for performing 
gene enrichment and network enrichment analyses.
Data alignment with the cancer genome atlas 
(TCGA) colorectal cancer
The top 100 upregulated genes and 100 downregulated genes 
from advanced stage vs. early stage comparison of  CD33+ 
myeloid cells were selected for analysis in the TCGA CRC 
dataset. Of these 100 upregulated genes, 99 genes were 
annotated in the TCGA CRC RNA-Seq dataset, of which 
55 genes (56%) had higher expression in patients with poorer 
disease-specific survival. For the 100 downregulated genes, 
96 genes were annotated in the TCGA dataset, of which 42 
genes (44%) had lower expression in patients with poorer 
disease-specific survival. The selected 55 upregulated and 
42 downregulated genes were used as the ‘poorer prognosis 
 CD33+ gene signature’ (ppCD33sig). The ppCD33sig score 
was calculated as the ratio of the average expression of the 
55 upregulated genes to the average of the 42 downregulated 
genes. Therefore, ppCD33sig was identified from data of our 
cohort and its prognostic significance was confirmed from 
the TCGA datasets.
Results
Characterization of sorted tumor‑infiltrating  CD33+ 
myeloid cells in CRC patients
CD33 is expressed on a heterogenous population of mye-
loid cells, and it does not distinguish MDSCs from TAMs 
or tumor-associated neutrophils (TANs) [20]. In addition, 
CD33 can be expressed on NK cells, but at lower levels 
compared to myeloid cell lineage [21, 22].  CD33high popu-
lations predominantly comprise monocytic populations and 
include cells with potentially high suppressive character-
istics as identified by several groups [23]. Therefore, we 
sorted  CD33high cells to avoid other cells expressing dim 
or low levels of CD33 from tumor tissues of CRC patients 
with varying disease stages to perform RNA-Seq. Data from 
RNA-Seq were analyzed using various bioinformatics tools. 
A schematic diagram of the overall study design is shown 
in Fig. 1.
RNA-Seq data analyses enabled us to confirm the purity 
of sorted populations by comparing transcriptomes of sorted 
tumor-infiltrating  CD33high cells with those of  CD8+ T cells 
from the same patients, and determine the gene expression 
levels of phenotypic markers for myeloid and lymphoid cell 
populations (Fig. 2a). We found that sorted tumor-infiltrating 
 CD33high cells expressed high levels of CD33 gene, while 
lacked gene expression of CD3E, CD8A and NCAM1 (gene 
for CD56), compared to  CD8+ T cells (Fig. 2a). Next, we 
investigated gene expression levels of myeloid phenotypi-
cal and functional markers within  CD33high cells to investi-
gate the heterogeneous populations, which constitute these 
cells. We found that tumor-infiltrating  CD33high cells showed 
high gene expression levels of CD36, CD14, FUT4 (CD15), 
CD80, CD86, CSF1R and immune checkpoint ligand 
genes including CD274 (PD-L1), LGALS9 (galectin-9), 
PVR and VSIR (Fig. 2b). Moreover, IL1B, IDO1, MMP1 
and CAECAM1/3/5/6 were also upregulated in  CD33high 
cells (Fig. 2b).
Next, we performed qRT-PCR to investigate and vali-
date mRNA expression levels of some key genes related 
to functional activity/recruitment or activation of myeloid 
cells including ARG1, IDO1, IL1B, CCR2, CD274 (PD-L1), 
LGALS9 (galectin-9) (Fig. 2c). We found all of these genes 
were expressed at significantly higher levels in  CD33high 
than  CD8+ T cells in the TME (Fig. 2c). Together, these 
data confirm the purity and functional activity of the sorted 
tumor-infiltrating  CD33high cells.
Transcriptomes and functional annotations 
of differentially expressed genes 
in tumor‑infiltrating  CD33+ myeloid cells in CRC 
patients with early and advanced stages
For differential gene expression analyses, we divided 
patients into two groups based on disease stage; early stage 
(stages I and II, n = 8) and advanced stage (stages III and 
IV, n = 5). We found 1,306 differentially expressed genes 
(DEGs) between tumor-infiltrating  CD33+ cells in CRC 
patients with early and advanced stages (Log2 FC ≥ 2 and 
P value cutoff ≤ 0.05, Supplementary Table 1). 239 genes 
were upregulated, while 1067 genes were downregulated 
in advanced stages (Fig. 3a). Hierarchical gene clustering 
across all patients is shown in Supplementary Fig. 1a.
To identify the functional pathways of DEGs from 
advanced versus early stage comparison, we performed 
gene ontology (BP) and KEGG pathway analyses using 
DAVID platform. We found that innate immune response-, 
response to hypoxia- and angiogenesis-related genes were 
significantly upregulated in advanced stages (P ≤ 0.05, 
Fig. 3b, c). On the other hand, genes related to inflamma-
tory response, T cell/NK cell activation, response to IFN-
γ, and chemokine-mediated signaling were significantly 
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downregulated in advanced stages, compared with early 
stages (P ≤ 0.05, Fig. 3b, c). These data suggest that adap-
tive anti-tumor immune responses could be compromised 
in advanced disease stages due to impaired innate immune 
responses initiated by exerted by myeloid cells.
We also generated enrichment networks of the downregu-
lated pathways to identify possible functional interactions in 
patients with advanced-stage compared to early-stage CRC 
(Supplementary Fig. 1b). We found that cell migration/
chemotaxis, chemokine-mediated signaling and immune 
response were downregulated in patients with advanced-
stage disease (Supplementary Fig. 1b). These data further 
confirm our functional pathways enrichment in  CD33+ TILs 
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Fig. 1  Schematic representation of study design. Tumor tissue speci-
mens from 13 CRC patients were used to sort highly pure  CD33high 
myeloid cells. Libraries were generated from sorted cells for RNA-
Seq. Different bioinformatics tools were utilized for analyses and vis-
ualization of RNA-Seq data. The experimental flowchart of this study 
is shown in (a), and the workflow for RNA-Seq data pre-processing 
and analysis using various bioinformatics tools is shown in (b)
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Fig. 2  Transcriptome analyses confirming the phenotypic and func-
tional characteristics of sorted  CD33+ myeloid cells. Tumor tissues 
from CRC patients were used to sort highly pure  CD33+ myeloid 
cells and  CD8+ T cells (used as controls), and differential gene 
expression analyses were performed on RNA-Seq data. Scatter plots 
show gene expression levels as the mean of Log10 TPM ± stand-
ard error of the mean (SEM) for CD33, CD3E, CD8A and NCAM1 
(gene for CD56) genes (a). Heatmap represents the fold change in 
gene expression levels of myeloid phenotypic and functional mark-
ers in  CD33+ vs.  CD8+ cells as Z-scores, which were calculated 
from TPM values (b). Bar plot shows the mRNA expression levels of 
ARG1, IDO, IL1B, IL6, CCR2, CD274 and LGALS9 in  CD33+ cells 
normalized to  CD8+ cells (used as controls), analyzed by qRT-PCR. 
The relative expression of each gene was calculated by normalization 
with β-actin. Mean + standard error of the mean (SEM) is shown in 
red (c). Statistical significance was calculated using non-parametric 
paired t-test; *P < 0.05; ***P < 0.001
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Analyses of functional pathways enriched 
in tumor‑infiltrating myeloid cells from various 
stages of CRC 
Next, we identified DEGs from stage-wise comparisons and 
subsequently investigated upregulated/downregulated path-
ways (Fig. 4a–c and Supplementary Table 1). We found that 
antigen processing and presentation- and NK cell-mediated 
cytotoxicity-related genes were enriched in stage II com-
pared to stage I (Fig. 4d). Complement and coagulation 
cascade-related genes were upregulated in stage IV com-
pared to stage I (Fig. 4d). This enrichment was also evident 
in advanced (A) vs early (E) stage comparisons (Fig. 4d). 
Similarly, enrichment of PPAR signaling-related genes in 
stage IV compared to stage II was also evident in advanced 
vs early comparison (Fig. 4d).
In contrast, we found that the majority of pathways were 
in the downregulated gene panel in stage comparisons. 
Cytokine–cytokine receptor interaction-related genes were 
significantly downregulated in all comparisons (Fig. 4e). 
In addition, inflammatory response-, TNF signaling- and 
PI3K–Akt signaling-related genes were also diminished 
in stage IV versus I (Fig. 4e); while PI3K–Akt signaling-, 
cell adhesion molecules-, MAPK- and TNF signaling-
related genes were also downregulated in stage IV vs II 
(Fig. 4e). Overall, cytokine–cytokine receptor interac-
tion-, chemokine signaling-, Toll-like receptor signal-
ing-, inflammatory response- and TCR signaling-related 
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Fig. 3  Transcriptome analyses of differentially expressed genes in 
tumor-infiltrating  CD33+ myeloid cells in CRC patients with early 
and advanced stage. We divided the patients into two groups based 
on disease stage; early stage (stages I and II, n = 8) and advanced 
stage (stages III and IV, n = 5), to compare their transcriptomic data. 
Volcano plot shows overall differentially regulated genes in patients 
with advanced stage compared to patients with early stage; red dots 
represent upregulated, green dots represent downregulated and gray 
dots represent genes, which remained unchanged with P values 
as a function of fold change and indicate the vertical dotted line to 
delimit > twofold change and P < 0.05 cutoffs (a). Bar plot shows 
functional annotations for the genes that were significantly upregu-
lated or downregulated in  CD33+ myeloid cells from advanced 
vs. early stages (b). Heatmaps show the Z-scores for various up- or 
downregulated genes and associated pathways in advanced vs. early 
stages (c)
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vs early stages (Fig.  4e). These results implicate that 
innate immune responses involved in T cell activation 
and immune cell recruitment could be compromised in 
advanced disease stages.
Analyses of steadily upregulated 
and downregulated genes in CRC patients 
with varying disease stages
Next, we investigated genes and their associated pathways, 
which were steadily upregulated (Supplementary Fig. 2a) 
or downregulated in tumor-infiltrating  CD33+ myeloid 
cells of CRC patients across disease stages (Stages I, II 
and IV) (Supplementary Fig. 2b). We found that particular 
genes were steadily upregulated (n = 33) and downregu-
lated (n = 267) across the stages. Genes such as human 
leukocyte antigen (HLA) complex genes HLA-DQA2/
HLA-DQB2 encoding HLA-Class II molecules [24], can-
cer/testis (CT) antigen XAGE1B [25] and FOLR genes, 
which are related to multiple cancers [26], were steadily 
upregulated in advanced stage. In contrast, several genes 
including interleukin-22 (IL22), epidermal growth factor 
Downregulated -1<=x<=1, P value<0.05Upregulated x<-1, P value>=0.05
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Fig. 4  Functional pathway analyses of deregulated genes from stage-
wise comparison. Differentially expressed genes from stage-wise 
comparisons were analyzed using the DAVID platform to identify 
functional pathway enrichments. Volcano plots show the deregulated 
genes obtained from stage II vs. I (a), IV vs. I (b), and IV vs. II (c). 
Bar charts show significantly upregulated (d) and downregulated (e) 
KEGG pathways enriched in each comparison, accompanied with the 
percentage of enriched genes in each pathway
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receptor (EGFR), and IL6 were downregulated stead-
ily with disease progression. These data implicate that 
tumor-infiltrating  CD33+ myeloid cells in advanced stages 
could have impaired activation and limited ability of cell 
proliferation.
Aligning DEGs with TCGA colorectal cancer reveals 
a gene signature of poor survival
The deregulated genes in  CD33+ cells in advanced disease 
stage were used to calculate the poor prognosis  CD33+ gene 
signature (ppCD33sig) score as described in the method sec-
tion and shown in Supplementary Table 2. The CRC TCGA 
cases were labeled as high, intermediate and low groups 
according to the ppCD33sig.
Patients with high ppCD33sig score had poorer disease-
specific survival (DSS) and shorter progression-free interval 
(PFI) compared to patients with intermediate or low ppCD-
33sig score (Fig. 5a, b). The ppCD33sig was an independent 
prognostic indicator for DSS (Fig. 5c) but not PFI (Fig. 5d), 
as indicated by multivariate analysis using Cox propor-
tional-hazard model even in the presence of disease stage as 
another indicator. Patients at advanced stages (III and IV) 
were more likely to have high ppCD33sig score (Fig. 5e). 
Patients with high ppCD33sig score were more likely to 
have residual disease after primary therapy (Fig. 5f). The 
splenic flexure, descending and sigmoid colon anatomical 
locations (left-sided colon cancer) were more likely to have a 
high ppCD33sig score whereas the transverse colon and the 
right-sided colon cancer (hepatic flexure, ascending colon 
and the cecum) were more likely to have a low ppCD33sig 
score (Supplementary Fig. 3a). The ppCD33sig score did not 
differ between males and female (Supplementary Fig. 3b) or 
age groups (Supplementary Fig. 3c). Next, we classified the 
patient cohort into two groups; high ppCD33sig score and 
low ppCD33sig score. We found that 6 patients with low 
and 7 patients with high ppCD33sig score (Supplementary 
Table 3). Hierarchical clustering showed 372 upregulated 
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Fig. 5  The prognostic significance of ‘poor prognosis  CD33+ gene 
signature’ (ppCD33sig) in the TCGA CRC dataset. Selected genes 
were used to determine the ppCD33sig score, calculated as the ratio 
of the average expression of the 55 upregulated genes to the aver-
age of the 42 downregulated genes. The ppCD33sig was evaluated 
in the TGCA CRC RNA-Seq dataset. Disease-specific survival (a) 
and progression-free interval (b) were compared between patients 
with high (top 33%), intermediate (middle 33%) or low (bottom 33%) 
ppCD33sig scores. The number (n) of patients in each of ppCD33sig 
groups and the Log-rank P value from Mantel–Cox test (GraphPad 
Prism v8.4) are indicated. Multivariate analyses using Cox propor-
tional-hazard model (MedCalculator v12.7) comparing the ppCD-
33sig (high, interm, low), disease stage (Stages IV, III, II, I), residual 
disease (yes, no), age (< 55, 55–64, 65–74, > 74  years of age), ana-
tomic locations (7 different locations), and sex (male, female) for dis-
ease-specific survival (DSS) (c) and progression-free interval (PFI) 
(d). Data shown are the hazard ratio (HR) ± 95% confidence interval 
(CI) and the multivariate P values are indicted (n.s.: not significant) 
(c, d). Distribution of patients with high, intermediate, or low ppCD-
33sig scores across disease stages (e). The presence of residual dis-
ease in patients with different ppCD33sig scores (f). Stated P values 
are from Chi-square (χ2) test was used
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and 1991 downregulated genes with Log2 FC > 2 and P 
value ≤ 0.05, when comparing high score with low score 
patients (Supplementary Fig. 3d). Moreover, our gene ontol-
ogy-biological process analyses showed that innate immune 
response/myeloid differentiation-related genes were upregu-
lated, while adaptive immune response/cell differentiation/
migration-related genes were downregulated in high score, 
compared with low ppCD33sig score patients (Supplemen-
tary Fig. 3e and Supplementary Table 4). Additionally, pro-
tein–protein interaction (PPI) and enrichment network analy-
ses revealed that innate immune responses-related genes, 
which were upregulated in patients with high ppCD33sig 
score, formed a significant network with P value of < 1.0E-
16 (Supplementary Fig. 4a). In contrast, adaptive immune 
responses related genes, which were downregulated genes 
in high ppCD33sig score also formed a significant network 
with P value of < 1.0E-16 (Supplementary Fig. 4b). These 
data further confirm our findings that in  CD33+ cells, innate 
immune responses were upregulated and adaptive responses 
were downregulated in advanced stages of CRC, compared 
with early stages.
Discussion
Transcriptomic profiling of myeloid cells has been previ-
ously carried out in different cancers [27]. However, it is 
of particularly higher significance in inflammation-related 
cancers, such as CRC, because of changes in the balance 
between different immune cell populations at the site of 
inflammation. Myeloid cells are the most common media-
tors of inflammation [28], however, some subsets of myeloid 
cells can act as potent immunosuppressive cells and have 
been detected in the CRC TME with high frequencies. We 
have previously reported the expansion of different MDSC 
subsets in the TME of CRC patients [11]. More recently, 
we reported the different epigenetic regulations and other 
molecular pathways in colorectal tumor-infiltrating MDSC 
subsets within TME, which could contribute to their expan-
sion and functionality [19]. In the present study, we investi-
gated the transcriptome of tumor-infiltrating myeloid cells 
to uncover molecular pathways, which are upregulated or 
downregulated in CRC patients as disease progresses from 
early to advanced stages.
Myeloid cell populations within the TME are plastic 
and heterogeneous with various phenotypical and molecu-
lar characteristics; the switch of tumor-infiltrating myeloid 
cells from a “pro-inflammatory” to “anti-inflammatory or 
immunosuppressive” can be triggered by multiple mecha-
nisms driven by tumor-induced factors, T regulatory cells or 
metabolic pathways [8, 29]. Dynamic interactions between 
different myeloid cell subsets and T cells within the TME 
are one of the key factors which dictate tumor progression 
[30]. Anti-tumor immune responses require a shift in the 
balance between immunosuppressive cells and potent T cell 
activation in favor of effective anti-tumor immunity and a 
pro-inflammatory environment instead of an immunosup-
pressive one [31].
CD33+ populations within the TME are enriched for 
HLA-DR– populations and comprise different MDSC sub-
sets, including  CD33+HLA-DR–CD14+CD15– monocytic 
MDSCs,  CD33+CD14+CD15– polymorphonuclear MDSCs 
and  CD33+HLA-DR–CD14–CD15– immature or early-stage 
MDSCs [32]. Since we did not sort HLA-DR− populations, 
the sorted cells comprise of a heterogeneous population of 
myeloid cell lineage, which primarily could include immu-
nosuppressive subsets of myeloid cells, such as MDSC and 
TAMs, but also include some HLA-DR-expressing APCs. 
The presence of these populations was evident in the tran-
scriptome of sorted cells, since genes encoding CD14, CD15 
(FUT4), and other myeloid cell phenotypic markers such 
as CD36, CD80 and CD86 were higher in sorted cells. In 
addition, the immunosuppressive potentials of  CD33high 
populations was confirmed by expressing high levels of 
immunosuppressive  factors, such as arginase-1 (ARG1) 
and indoleamine-pyrrole 2,3-dioxygenase (IDO), inhibitory 
immune checkpoint ligands, such as PD-L1 and galectin-9, 
and cytokines important for MDSC recruitment and func-
tion/activation, such as CCR2, IL-1β and IL-6 [33].
CD33high populations comprise of diverse monocytic 
cell populations involved in lymphocyte recruitment and 
also in immunosuppression [7]. Moreover, the presence of 
 CD33high immunosuppressive monocytes has been recorded 
in various cancers [34, 35]. We found that genes related to 
numerous vital immune modulatory pathways, including the 
regulation of T cell/NK cell activation and response to IFN-
γ, were downregulated in myeloid cells from patients with 
advanced disease stage, compared to those with early stages. 
These results implicate that myeloid cells in advanced stage 
disease could lose their pro-inflammatory properties and 
acquire pro-tumorigenic properties promoting the suppres-
sion of anti-tumor immunity, primarily T cell and NK cell 
activation, and supporting tumor progression. NK cells are 
considered as primary innate immune cells with anti-tumor 
activity against non-MHC-expressing tumor cells [36]. Here, 
we found that genes related to NK cell activation were down-
regulated in tumor-infiltrating myeloid cells from advanced 
stage patients, suggesting the limited activity of NK cells in 
progressive disease stages.
Importantly, we found that genes related to innate 
immune responses were upregulated, while genes related 
to adaptive immune responses were downregulated 
in tumor-infiltrating myeloid cells from patients with 
advanced stage. M2 macrophages, TAMs and MDSC con-
stitute innate immune cells, which augment tumor growth, 
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invasion and metastasis, and have been previously associ-
ated with aggressive CRC tumors [37]. Moreover, it has 
been reported that increased levels of suppressive mye-
loid cells in the TME could be responsible for regulating 
adaptive immune responses [38]. In addition, we found 
that cell chemotaxis-, myeloid leukocyte migration-, and 
chemokine-mediated signaling-related genes were down-
regulated in patients with advanced stage. Immune cell 
migration is critical in prompting immune responses and 
dictates outcomes of different pathological conditions, 
especially inflammation-related cancers such as CRC 
[39]. These data show that inactivation/impaired adaptive 
immune responses could play a vital role in CRC disease 
progression.
Myeloid suppressor cells can support tumor growth by 
favoring angiogenesis, suppressing immune responses and 
promoting metastasis [40]. Our data provide evidence that 
MMP9, known to be associated with the ‘angiogenic switch’ 
[41] was upregulated in patients with advanced stage. In 
concordance with these evidences, genes related to the posi-
tive regulation of angiogenesis and response to hypoxia were 
also upregulated in tumor-infiltrating myeloid cells from 
patients with advanced stage, potentially suggesting that 
hypoxia can switch on genes in tumor-infiltrating myeloid 
cells to drive angiogenesis and consequently metastasis in 
patients with advanced disease stage. Hypoxia occurs in 
most growing solid tumors as a result of increased oxygen 
consumption by growing tumor cells and has been associ-
ated with tumor aggressiveness and resistance to therapy 
[42]. Additionally, hypoxia can affect the plasticity and 
heterogeneity of tumor cells, alter the phenotypic states of 
immune cells, including myeloid cells, and induce several 
pathways that support tumor growth and progression, such 
as angiogenesis [29, 42]. Our results suggest a plausible link 
between hypoxia and disease progression via myeloid cells 
with potential immunosuppressive properties. Moreover, we 
found some CT antigen-related genes were upregulated in 
tumor-infiltrating myeloid cells in advanced stages. Certain 
CT antigens have been previously identified as prognos-
tic biomarkers for CRC progression [43]. Our data show 
that CT antigens may be expressed on tumor-infiltrating 
myeloid cells and could be explored as biomarkers for CRC 
progression.
It is vital to note that while our results provided evidence 
for the regulation of various genes in tumor-infiltrating mye-
loid cells in CRC patients with different disease stages, the 
affected pathways and the functional significance of these 
data require further investigations to validate these findings. 
Our data indicate various pathways by which myeloid cells 
could contribute to the progression of CRC. In an attempt 
to decipher the clinical relevance of our data, we aligned 
the top upregulated/downregulated genes with the TCGA 
CRC RNA-Seq data, and identified “the poorer prognosis 
 CD33+ gene signature”. We found that this gene signature is 
an independent prognostic indicator for DSS (timeframe of 
diagnosis until death), but not PFI (survival timeframe with-
out worsened disease outcomes). These results suggest the 
potential specificity of the gene signature identified to sur-
vival rates, without having an impact on disease progression.
Based on TCGA analyses, we also showed that patients at 
advanced stages were more likely to have high ppCD33sig 
score, and patients with high ppCD33sig score were more 
likely to have residual disease after primary therapy. These 
findings implicate the potential link between high ppCD-
33sig score, tumor recurrence and tumor resistance to ther-
apy. In line with this, several reports have demonstrated the 
clinical significance of colorectal tumor-infiltrating myeloid 
cells in dictating tumor relapse and influencing the response 
to therapy [44]. Cytokines and chemokines within the TME 
are crucial soluble factors which determine the nature of the 
TME (i.e., suppressive or pro-inflammatory) and can orches-
trate the function of immune cells and regulate their migra-
tion and accumulation at tumor sites [45]. Coincidently, we 
found that innate immune response-related genes, such as 
cytokines and chemokines, were significantly upregulated 
in high ppCD33sig score; these chemokines and cytokines 
are more likely to be involved with the chemotaxis, differen-
tiation and survival of tumor cells and immunosuppressive 
cells, including Tregs, TAMs and MDSCs [8, 10]. On the 
other hand, genes associated with the activation of adaptive 
immune response were significantly downregulated in CRC 
patients with high ppCD33sig score, indicating the suppres-
sive potential of tumor- infiltrating myeloid cells in these 
patients. These findings further support our previous results 
obtained by comparing the transcriptomes of tumor-infiltrat-
ing myeloid cells from advanced vs. early stages.
Overall, this study provides critical insights into the 
pathways affected in tumor-infiltrating myeloid cells dur-
ing the progression of CRC and their potential contribu-
tion to disease progression, and identifies a  CD33+ gene 
signature which predicts poor disease-specific survival in 
CRC patients. However, further validations are required for 
the functional attributes of the identified gene signature in 
myeloid cells.
Availability of data and material
The datasets used and/or analyzed during the current study 
are available from the corresponding author on request.
Acknowledgements We are grateful to Dr Fares Al-Ejeh from Cancer 
Research Center, Qatar Biomedical Research Institute, for assisting in 
data alignment with TCGA datasets and data presentation/visualization 
of results. We would also like to thank the genomics core facility at 
Qatar Biomedical Research Institute for performing RNA-Sequencing. 
814 Cancer Immunology, Immunotherapy (2021) 70:803–815
1 3
We are also thankful to Ms Eleonor Dela Cruz Belita and Mr Mark 
Edison Baladad from Hamad Medical Corporation for assisting in 
acquiring patient samples, and all patients for donating their samples.
Funding Open Access funding was provided by the Qatar National 
Library. This work was supported by a start-up grant [VR04] for 
Prof. Eyad Elkord from Qatar Biomedical research Institute, Qatar 
Foundation.
Compliance with ethical standards 
Conflict of interests The authors declare no conflicts of interest.
Ethics approval and consent to participate This study was executed 
under ethical approvals from Hamad Medical Corporation, Doha, Qatar 
(Protocol no. MRC-02-18-012) and Qatar Biomedical Research Insti-
tute, Doha, Qatar (Protocol no. 2017-006).
Consent for publication Not applicable.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A 
(2018) Global cancer statistics 2018: GLOBOCAN estimates of 
incidence and mortality worldwide for 36 cancers in 185 coun-
tries. CA Cancer J Clin 68(6):394–424. https ://doi.org/10.3322/
caac.21492 
 2. Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, 
Rodriguez Yoldi MJ (2017) Colorectal carcinoma: a general over-
view and future perspectives in colorectal cancer. Int J Mol Sci. 
https ://doi.org/10.3390/ijms1 80101 97
 3. Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal 
cancer: incidence, mortality, survival, and risk factors. Prz Gas-
troenterol 14(2):89–103. https ://doi.org/10.5114/pg.2018.81072 
 4. Estevez-Garcia P, Rivera F, Molina-Pinelo S, Benavent M, Gomez 
J, Limon ML, Pastor MD, Martinez-Perez J, Paz-Ares L, Carnero 
A, Garcia-Carbonero R (2015) Gene expression profile predic-
tive of response to chemotherapy in metastatic colorectal cancer. 
Oncotarget 6(8):6151–6159. https ://doi.org/10.18632 /oncot arget 
.3152
 5. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, 
adaptive, and acquired resistance to cancer immunotherapy. Cell 
168(4):707–723. https ://doi.org/10.1016/j.cell.2017.01.017
 6. Engblom C, Pfirschke C, Pittet MJ (2016) The role of myeloid 
cells in cancer therapies. Nat Rev Cancer 16(7):447–462. https ://
doi.org/10.1038/nrc.2016.54
 7. Olingy CE, Dinh HQ, Hedrick CC (2019) Monocyte heterogeneity 
and functions in cancer. J Leukoc Biol 106(2):309–322. https ://
doi.org/10.1002/JLB.4RI08 18-311R
 8. Saleh R, Elkord E (2019) Treg-mediated acquired resistance to 
immune checkpoint inhibitors. Cancer Lett 457:168–179. https ://
doi.org/10.1016/j.canle t.2019.05.003
 9. Gabrilovich DI (2017) Myeloid-derived suppressor cells. Can-
cer Immunol Res 5(1):3–8. https ://doi.org/10.1158/2326-6066.
CIR-16-0297
 10. Zhang S, Ma X, Zhu C, Liu L, Wang G, Yuan X (2016) The 
role of myeloid-derived suppressor cells in patients with solid 
tumors: a meta-analysis. PLoS ONE 11(10):e0164514. https ://
doi.org/10.1371/journ al.pone.01645 14
 11. Toor SM, Syed Khaja AS, El Salhat H, Bekdache O, Kanbar J, 
Jaloudi M, Elkord E (2016) Increased levels of circulating and 
tumor-infiltrating granulocytic myeloid cells in colorectal cancer 
patients. Front Immunol 7:560. https ://doi.org/10.3389/fimmu 
.2016.00560 
 12. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, Guo HF, 
Miao ZN (2012) Increased frequency and clinical significance of 
myeloid-derived suppressor cells in human colorectal carcinoma. 
World J Gastroenterol 18(25):3303–3309. https ://doi.org/10.3748/
wjg.v18.i25.3303
 13. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, 
Zhao K (2013) Circulating and tumor-infiltrating myeloid-derived 
suppressor cells in patients with colorectal carcinoma. PLoS ONE 
8(2):e57114. https ://doi.org/10.1371/journ al.pone.00571 14
 14. Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu Nada 
M, Elkord E (2019) Immune checkpoints in circulating and 
tumor-infiltrating CD4(+) T cell subsets in colorectal cancer 
patients. Front Immunol 10:2936. https ://doi.org/10.3389/fimmu 
.2019.02936 
 15. Toor SM, Sasidharan Nair V, Pfister G, Elkord E (2019) Effect 
of pembrolizumab on CD4(+) CD25(+), CD4(+) LAP(+) and 
CD4(+) TIM-3(+) T cell subsets. Clin Exp Immunol 196(3):345–
352. https ://doi.org/10.1111/cei.13264 
 16. Saleh R, Sasidharan Nair V, Toor S, Taha R, Murshed K, Al-
Dhaheri M, Khawar M, Petkar M, Abu Nada M, Al-Ejeh F, Elkord 
E (2020) Differential gene expression of tumor-infiltrating CD8+ 
T cells in advanced versus early-stage colorectal cancer and iden-
tification of a gene signature of poor prognosis. J Immunother 
Cancer 8:e001294. https ://doi.org/10.1136/jitc-2020-00129 4
 17. Vishnubalaji R, Sasidharan Nair V, Ouararhni K, Elkord E, Ala-
jez NM (2019) Integrated transcriptome and pathway analyses 
revealed multiple activated pathways in breast cancer. Front 
Oncol. https ://doi.org/10.3389/fonc.2019.00910 .10.3389/
fonc.2019.00910 
 18. Malone BM, Tan F, Bridges SM, Peng Z (2011) Comparison of 
four ChIP-Seq analytical algorithms using rice endosperm H3K27 
trimethylation profiling data. PLoS ONE 6(9):e25260. https ://doi.
org/10.1371/journ al.pone.00252 60
 19. Sasidharan Nair V, Saleh R, Toor SM, Taha RZ, Ahmed AA, 
Kurer MA, Murshed K, Alajez NM, Abu Nada M, Elkord E (2020) 
Transcriptomic profiling disclosed the role of DNA methylation 
and histone modifications in tumor-infiltrating myeloid-derived 
suppressor cell subsets in colorectal cancer. Clin Epigenetics. 
https ://doi.org/10.1186/s1314 8-13020 -10808 -13149;10.1186/
s1314 8-020-0808-9
 20. Elliott LA, Doherty GA, Sheahan K, Ryan EJ (2017) Human 
tumor-infiltrating myeloid cells: phenotypic and functional 
diversity. Front Immunol 8:86. https ://doi.org/10.3389/fimmu 
.2017.00086 
 21. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ 3rd, 
York VA, Ndhlovu LC, Lanier LL, Michaelsson J, Nixon DF 
(2009) Functionally distinct subsets of human NK cells and 
815Cancer Immunology, Immunotherapy (2021) 70:803–815 
1 3
monocyte/DC-like cells identified by coexpression of CD56, CD7, 
and CD4. Blood 114(23):4823–4831. https ://doi.org/10.1182/
blood -2009-04-21637 4
 22. Eckel AM, Cherian S, Miller V, Soma L (2020) CD33 expres-
sion on natural killer cells is a potential confounder for residual 
disease detection in acute myeloid leukemia by flow cytometry. 
Cytometry Part B Clin Cytometry 98(2):174–178. https ://doi.
org/10.1002/cyto.b.21846 
 23. Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, 
Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, 
Welters MJ, Walter S (2016) Toward harmonized phenotyping 
of human myeloid-derived suppressor cells by flow cytometry: 
results from an interim study. Cancer Immunol Immunother 
65(2):161–169. https ://doi.org/10.1007/s0026 2-015-1782-5
 24. Lenormand C, Bausinger H, Gross F, Signorino-Gelo F, Koch 
S, Peressin M, Fricker D, Cazenave JP, Bieber T, Hanau D, de la 
Salle H, Tourne S (2012) HLA-DQA2 and HLA-DQB2 genes are 
specifically expressed in human Langerhans cells and encode a 
new HLA class II molecule. J Immunol 188(8):3903–3911. https 
://doi.org/10.4049/jimmu nol.11030 48
 25. Taguchi A, Taylor AD, Rodriguez J, Celiktas M, Liu H, Ma X, 
Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, 
Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM (2014) 
A search for novel cancer/testis antigens in lung cancer identi-
fies VCX/Y genes, expanding the repertoire of potential immu-
notherapeutic targets. Cancer Res 74(17):4694–4705. https ://doi.
org/10.1158/0008-5472.CAN-13-3725
 26. Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kacher-
gus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia 
A, O’Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, 
Cunliffe HE, Ballman KV, Thompson EA, Perez EA (2015) Folate 
receptor-alpha (FOLR1) expression and function in triple negative 
tumors. PLoS ONE 10(3):e0122209. https ://doi.org/10.1371/journ 
al.pone.01222 09
 27. Cieslik M, Chinnaiyan AM (2018) Cancer transcriptome profiling 
at the juncture of clinical translation. Nat Rev Genet 19(2):93–
109. https ://doi.org/10.1038/nrg.2017.96
 28. Schmid MC, Varner JA (2010) Myeloid cells in the tumor micro-
environment: modulation of tumor angiogenesis and tumor inflam-
mation. J Oncol 2010:201026. https ://doi.org/10.1155/2010/20102 
6
 29. Ke X, Chen C, Song Y, Cai Q, Li J, Tang Y, Han X, Qu W, Chen 
A, Wang H, Xu G, Liu D (2019) Hypoxia modifies the polari-
zation of macrophages and their inflammatory microenviron-
ment, and inhibits malignant behavior in cancer cells. Oncol Lett 
18(6):5871–5878. https ://doi.org/10.3892/ol.2019.10956 
 30. Toh B, Toh B, Abastado JP, Abastado JP (2012) Myeloid cells: 
Prime drivers of tumor progression. Oncoimmunology 1(8):1360–
1367. https ://doi.org/10.4161/onci.22196 
 31. Kaufman HL, Disis ML (2004) Immune system versus tumor: 
shifting the balance in favor of DCs and effective immunity. J Clin 
Invest 113(5):664–667. https ://doi.org/10.1172/JCI21 148
 32. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten 
TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, 
Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich 
DI (2016) Recommendations for myeloid-derived suppressor 
cell nomenclature and characterization standards. Nat Commun 
7:12150. https ://doi.org/10.1038/ncomm s1215 0
 33. Nakamura K, Smyth MJ (2020) Myeloid immunosuppression and 
immune checkpoints in the tumor microenvironment. Cell Mol 
Immunol 17(1):1–12. https ://doi.org/10.1038/s4142 3-019-0306-1
 34. Crispen PL, Kusmartsev S (2020) Mechanisms of immune evasion 
in bladder cancer. Cancer Immunol Immunother 69(1):3–14. https 
://doi.org/10.1007/s0026 2-019-02443 -4
 35. Okla K, Czerwonka A, Wawruszak A, Bobinski M, Bilska M, 
Tarkowski R, Bednarek W, Wertel I, Kotarski J (2019) Clini-
cal relevance and immunosuppressive pattern of circulating and 
infiltrating subsets of myeloid-derived suppressor cells (MDSCs) 
in epithelial ovarian cancer. Front Immunol 10:691. https ://doi.
org/10.3389/fimmu .2019.00691 
 36. Liu Y, Zeng G (2012) Cancer and innate immune system interac-
tions: translational potentials for cancer immunotherapy. J Immu-
nother 35(4):299–308. https ://doi.org/10.1097/CJI.0b013 e3182 
518e8 3
 37. Grizzi F, Bianchi P, Malesci A, Laghi L (2013) Prognostic value 
of innate and adaptive immunity in colorectal cancer. World J 
Gastroenterol 19(2):174–184. https ://doi.org/10.3748/wjg.v19.
i2.174
 38. Frey AB (2006) Myeloid suppressor cells regulate the adaptive 
immune response to cancer. J Clin Invest 116(10):2587–2590. 
https ://doi.org/10.1172/JCI29 906
 39. Norton SE, Ward-Hartstonge KA, Taylor ES, Kemp RA (2015) 
Immune cell interplay in colorectal cancer prognosis. World J 
Gastrointest Oncol 7(10):221–232. https ://doi.org/10.4251/wjgo.
v7.i10.221
 40. Pastaki Khoshbin A, Eskian M, Keshavarz-Fathi M, Rezaei N 
(2019) Roles of myeloid-derived suppressor cells in cancer 
metastasis: immunosuppression and beyond. Archivum Immu-
nologiae et Therapiae Experimentalis 67(2):89–102. https ://doi.
org/10.1007/s0000 5-018-0531-9
 41. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, 
Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) 
Matrix metalloproteinase-9 triggers the angiogenic switch dur-
ing carcinogenesis. Nat Cell Biol 2(10):737–744. https ://doi.
org/10.1038/35036 374
 42. Terry S, Faouzi Zaarour R, Hassan Venkatesh G, Francis A, El-
Sayed W, Buart S, Bravo P, Thiery J, Chouaib S (2018) Role of 
hypoxic stress in regulating tumor immunogenicity, resistance and 
plasticity. Int J Mol Sci. https ://doi.org/10.3390/ijms1 91030 44
 43. Tarnowski M, Czerewaty M, Deskur A, Safranow K, Marlicz W, 
Urasinska E, Ratajczak MZ, Starzynska T (2016) Expression of 
cancer testis antigens in colorectal cancer: new prognostic and 
therapeutic implications. Dis Markers 2016:1987505. https ://doi.
org/10.1155/2016/19875 05
 44. Guo L, Wang C, Qiu X, Pu X, Chang P (2020) Colorectal Cancer 
Immune Infiltrates: Significance in Patient Prognosis and Immu-
notherapeutic Efficacy. Front Immunol. https ://doi.org/10.3389/
fimmu .2020.01052 
 45. Amedei A, Prisco D, MM DE, (2013) The use of cytokines and 
chemokines in the cancer immunotherapy. Recent Pat Anti-Cancer 
Drug Discovery 8(2):126–142
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
